California’s troubled unemployment agency squandered $4.6M on cell phones, devices that sat unused

The California State Auditor revealed that the agency, better known as EDD, wasted more than $4.6 million on monthly service ...

State agency wasted $4.6 million on thousands of unused cell phones, audit shows

Surge in unemployment claims prompts Employment Development Department to buy thousands of cell phones, but they weren’t used, audit finds.

BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least

BridgeBio Oncology Therapeutics (BBOT) targets KRAS and PI3Ka malignancies with next-generation small molecule therapeutics, ...

FDA approves first new antibiotics to treat gonorrhea in decades, with hope to combat drug resistance

And GSK announced Thursday that the FDA had approved its medication gepotidacin, with the brand name Blujepa, as oral tablets ...

Indiana Senate panel testimony favors total student phone ban

A tougher crackdown on student cell phones in schools is being considered by Hoosier lawmakers, just one year after they ...
NC Biotech

Mucommune wins federal funding to develop novel CAR-T cancer therapy

Mucommune, a Morrisville-based biotechnology company with roots at the University of North Carolina at Chapel Hill, has been ...
The Scientist

RSV Infection and Mom’s Allergies Heighten Babies’ Asthma Risk

Early-life viral infection programs immune cells to hijack allergy-associated maternal antibodies, driving allergy risk later ...

CAR T-cell therapy accelerates intestinal healing in aging mice

Ever notice that as you get older, some foods no longer sit with you the same? This could be due to a breakdown of the ...
MedPage Today

Gene Therapy-Induced CAR T Cells for Myeloma Could Alter Treatment Landscape

ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...
Science Daily

Gene-edited CAR-T cells erase aggressive T-cell leukemia

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition

Immix Biopharma is advancing NXC-201, showing 95% complete/near-complete response rates and superior safety. Learn why IMMX ...
EurekAlert!

Personalised cancer medicine: New insights into the benefits and risks of therapies

In a translational study led by the University of Leipzig Medical Center and the Fraunhofer IZI, researchers have examined how two innovative CAR T-cell therapies targeting the B-cell maturation ...